Invasive ductal breast carcinoma
MONDO:0004953The most common type of invasive breast carcinoma, accounting for approximately 70% of breast carcinomas. The gross appearance is usually typical with an irregular stellate outline. Microscopically, randomly arranged epithelial elements are seen. When large sheets of malignant cells are present, necrosis may be seen. With adequate tissue sampling, in situ carcinoma can be demonstrated in association with the infiltrating carcinoma. The in situ component is nearly always ductal but occasionally may be lobular or both.
Also known as: infiltrating ductal adenocarcinoma, infiltrating ductal breast carcinoma, infiltrating ductal carcinoma, infiltrating ductal carcinoma of breast, infiltrating ductal carcinoma of the breast, invasive ductal adenocarcinoma, invasive ductal breast carcinoma, invasive ductal carcinoma
2844 clinical trials for this condition and its sub-types, 41 tagged with Invasive ductal breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Invasive ductal breast carcinoma
-
Basal-like breast carcinoma 5 trials
-
Invasive tubular breast carcinoma 5 trials
-
Medullary breast carcinoma 2 trials
-
Breast mucinous carcinoma 1 trial
1 sub-type
-
Breast secretory carcinoma 1 trial
1 sub-type
-
Acinic cell breast carcinoma 0 trials
-
Pleomorphic breast carcinoma 0 trials
-
Scirrhous breast carcinoma 0 trials
-
Breast cancer radiation showdown: 3D vs internal implants
Disease control Stopped earlyThis study compared two types of radiation given after breast-conserving surgery for early-stage breast cancer: 3D conformal radiation (external beams) and internal brachytherapy (radioactive material placed in the breast). Only 6 women took part before the trial was stopped earl…
Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Gene study may explain why some breast cancers resist hormone therapy
Knowledge-focused Stopped earlyThis study looked at whether a specific gene mutation (HSD3B1) changes how well the hormone therapy letrozole works in postmenopausal women with early-stage, hormone-sensitive breast cancer. Researchers measured changes in tumor markers before and after treatment. The trial was e…
Phase 4 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC